

## **STEFANO VELLA, MD**

### ***Education***

- Degree in Medicine, University of Rome, 1977
- Specialty in Infectious Diseases, University of Rome, 1982
- Specialty in Internal Medicine, University of Rome, 1988

### ***Current Positions***

- Adjunct Professor, Global Health, Catholic University of Rome (UCSC)
- Associate Professor, Clinical Research Methodology, University of Tor Vergata, Rome
- Adjunct Professor, Health Policies in Europe, LUISS University, Rome
- Research Associate, Department of Global Public Health, Karolinska Institutet, Stockholm,
  - Member, Italian Delegation, Program Committee, HORIZON EUROPE, (2021-2027),  
Health Cluster, European Commission, Bruxelles
  - Senior Consultant, UNITAID, Geneva (2021)
  - Vice President, Friends of the Global Fund (Europe GFTAM)
- Chair, Data and Safety Monitoring Committees, EU-RESPONSE Clinical Trials Platform
- Member, Technical Advisory Panel, Pandemic Fund, World Bank & WHO

### ***Previous Positions***

- Director, National Center for Global Health,  
*Istituto Superiore di Sanità (the Italian National Institute for Health) – Rome (2017 – 2019)*
- President, Italian Medicines Agency – AIFA (2017 – 2018)
- Director, Department of Pharmacology, Istituto Superiore di Sanità (2003-2017)
- Research Director, Laboratory of Virology, Istituto Superiore di Sanità (1991-2003)
- Clinical Staff, Internal Medicine, University of Rome “La Sapienza” (1977 - 1991)

### ***Languages***

Fluent in English, French and Spanish

### ***Honours***

Cavaliere della Repubblica Italiana (1999)      Commendatore della Repubblica Italiana (2018)

## ***Past Appointments***

- President, International AIDS Society [IAS] (2000-2002)
  - Co-Organizer, International AIDS Conference, Durban, South Africa (2000)
    - Italian Delegation, UNGASS, NY, (2001)
  - Program Coordinating Board, UNAIDS (2000-2004)
- Technical Review Panel, Global Fund to fight Tuberculosis, AIDS and Malaria, (2004-2005)
  - Board Member, Global Fund to fight Tuberculosis, AIDS and Malaria (2006-2007)
- Scientific and Technical Scientific Committee (STAC), UNAIDS, Geneva (2016 – 2018)
- Vice- Chair, Board (European and Developing Countries Clinical Trial Partnership) - EC
  - Chair, Clinical Panel for the revision of antiretroviral guidelines, WHO (2013)
  - Core Group, Panel for the revision of antiretroviral guidelines, WHO (2016)
    - Vice-President, Friends of Global Fund - Europe
    - Advisor, Medicines Patent Pool (MPP), Geneva
      - Senior Advisor, UNITAID, Geneva
        - T20, ITALY 2021

## ***Drug Development and Regulatory***

- Scientific Advice Working Party, EMEA, London (2003-2007)
- Scientific and Technical Committee (CTS), the Italian Medicines Agency (2003 – 2007)
  - President, Italian Medicines Agency – AIFA (2017-2018)

## ***European Research***

- Member, Program Committee, 7<sup>th</sup> Framework Program, Health Research, EC (2007- 2013)
- Italian Representative, Program Committee, Horizon Europe, Health Cluster (2021 – 2027)

## ***Basic, Clinical and Public Health Research***

- Chair, European Clinical Network for the Treatment of HIV/AIDS (NEAT, 2006-2012)
- Work Package Leader, European HIV Vaccine Alliance, EC funded project (2015-2019)
- Work Package Leader, FRESHER, NCDs Foresight Research Program, EC funded (2015 – 2018)
  - Vice-President, Scientific Advisory Board, ANRS, Paris, France (2011-2016)
  - Member, Antiretroviral Strategy Science Committee, ACTG, NIAID, NIH, USA
- Member of the Executive and Chair, External Relations, NEAT-ID Foundation, London

## Publications

STEFANO VELLA

<https://publons.com/researcher/ABI-3368-2020/>  
Web of Science ResearcherID: ABI-3368-2020

## Publications

### PUBLICATION METRICS

For all time

CITATIONS

17100

H-INDEX

55


PUBLICATIONS

316

WEB OF SCIENCE PUBLICATIONS

316

### PUBLICATION IMPACT OVER TIME



## Contacts

[stefano.vella08@gmail.com](mailto:stefano.vella08@gmail.com) / [stefano.vella@unicatt.it](mailto:stefano.vella@unicatt.it)

Mobile: +39 3482650598

February 2023

*Stefano Vella*

## Biosketch

Stefano Vella (born in Rome, June 12, 1952) received his degree in Medicine from the University of Rome, in 1977. He subsequently achieved specialty degrees in both Infectious Diseases (1982) and Internal Medicine (1987).

After a postdoctoral experience at the University of Pennsylvania (1981-1982), he joined the medical staff at the Institute of Internal Medicine, University La Sapienza, Rome, where he developed an extensive experience in the clinical management of internal medicine and infectious diseases patients.

In 1992, he was appointed Research Director of HIV/AIDS at the Istituto Superiore di Sanità (ISS), the Italian National Institute of Health. Specific work has been conducted by Dr Vella and his research group on the clinical development of antiretroviral therapy; the study of HIV resistance to antiretroviral drugs; the mechanisms of immune reconstitution; the care and treatment of co-infections, including TB; the area of health needs assessment; the area of operational and implementation research in resource limited settings. At the beginning of the era of combination antiretroviral treatment, he chaired - or participated to - numerous international clinical studies on antiretroviral therapy, including the first studies with protease inhibitors and non-nucleoside reverse transcriptase inhibitors, and strategic studies to assess the best first-line and second line regimens. As a consequence of his work, he was appointed to the Panel who developed the first HIV treatment guidelines (JAMA, 1996).

Since 1996, as Member of the Governing Council of the International AIDS Society [IAS] and subsequently as IAS President (2000-2002), he actively worked towards promoting access to treatment and care in the South of the World. He has been instrumental for the organization of the AIDS Conference in Durban, South Africa (2000). He subsequently chaired the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001, and the XIV International Conference on AIDS, Barcelona, 2002

From 2003 till 2016, he has been the Director of Department of Pharmacology and Therapeutic Research at ISS (2003-2016), overseeing the research activities of over 270 staff members. In this position he conducted studies on therapeutics of major human disease areas.

He has been a member (2004-2007) of the Scientific Advice Working Group (SAWG) of the European Medicines Agency (EMA), London, where he acquired an extensive expertise in the regulatory aspects of the clinical development of medicines, from the preclinical phase to phase III clinical trials.

In 2013, he chaired the Panel who developed the WHO Guidelines on HIV Treatment and Care and was member of the panel who revised the guidelines in 2016.

Dr Vella has served as Vice President of the Scientific Council, ANRS (*Agence Nationale de Recherche sur le Sida et les hépatites virales*), Paris, France (2015-2018)

Since 2014 until 2017, he has been a member of the Strategic Agenda Committee of the Aids Clinical Trials Group ACTG, NIAID, NIH, Bethesda MD, USA

Dr Vella has been a Member of Technical Review Panel (TRP) of the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), 2003-2004, where he acquired an extensive experience in the evaluation of country programs to fight poverty-related diseases.

He subsequently served as the Italian Member of the Board of the GFTAM (2006-2007), and is currently a member of the Italian Constituency.

In January 2017, Dr Vella was appointed Director of the Italian Center for Global Health at the National Institute of Health, whose mission is to fight health inequalities worldwide through research, education and advocacy. From March 2017 till June 2018, he served as President of the Board of the Italian Medicines Agency (AIFA). He resigned in august 2018, because his disagreement with the policy of the Italian Government of that time regarding the health of migrants.

SV is currently Vice-President of the Friends of Global Fund – Europe, where he worked for the promotion Global Fund and the fight against AIDS, Tuberculosis and Malaria, building partnerships/alliances with key high-level stakeholders and with political decision-makers. He fostered the return of Italy to the list of GFTAM in 2013 and 2016.

From 2016 till 2018 he has been a member of the UNAIDS Scientific and Technical Advisory Committee (STAC).

SV has been and is currently involved in operational and implementation programs in Ethiopia (HIV community care), Malawi (mother and child health), Angola (Tuberculosis), and is a partner of a large, EDCTP funded, randomized trial (PREGART) comparing three regimens for the treatment of pregnant women in Ethiopia and Uganda.